Emerging Innovators: Q3 Updates

Back

FAST / CARB-X / Emerging Innovators News

Applied Molecular Transport, LLC. (FAST Spring 2014) (Nasdaq: AMTI), a clinical-stage biopharmaceutical company, today announced additional Phase 1b data for oral AMT-101 in ulcerative colitis (UC) patients. Read more

GigaGen Inc. (FAST Spring 2015), a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research in BioRxiv entitled, “Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy.” Read more

Encellin, (FAST Fall 2017), a personalized regenerative medicine biotech company developing novel cell-based approaches to deliver sustained therapies with a single implant, today announced the closing of a $5.9M Seed financing round. The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator. Read more

CARB-X is awarding SNIPR BIOME ApS, a CRISPR- and microbiome-biotechnology company in Copenhagen, Denmark, up to US $3.9 million to develop an innovative new drug to prevent E. coli infections in cancer patients, which can be life-threatening. Under the award, SNIPR BIOME may be eligible for up to $6.3 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds. Read more

CARB-X is awarding BioVersys, a pharmaceutical company headquartered in Basel, Switzerland, up to US$4.35 million in non-dilutive funding, to develop a new class of antibiotics to treat life-threatening infections caused by ESKAPE pathogens, bacteria that have developed resistance to most antibiotics available today. BioVersys could receive up to $10.98 million in additional funds from CARB-X if the project achieves certain milestones, subject to available funds. Read more

CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds. Read more

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership led by Boston University, is celebrating five years of progress in funding and supporting the development of innovative products targeting antibiotic-resistant bacteria. Since it was founded in July 2016, CARB-X has invested $361 million in non-dilutive funding to develop innovative therapeutics including new classes of antibiotics and non-traditional agents, vaccines and other preventatives such as CRISPR-phage, microbiome-modifying agents and antibodies, and rapid diagnostics. Read more